Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus antidepressants for non-suicidal self-injury in adolescents
ChiCTR2000041457Phase 4Recruiting
- Sponsor
- Chaohu Hospital of Anhui Medical University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine in major depressive disorder (MDD) and nonsuicidal self-injury (NSSI), sponsored by Chaohu Hospital of Anhui Medical University. Primary endpoints: Chinese version of the Functional Assessment of Self-Mutilation (C-FASM), Hamilton Rating Scale for Depression (HAMD) and 3 more. Started Jan 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)nonsuicidal self-injury (NSSI)
Beyond the preview
Go deeper on ChiCTR2000041457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041457.